Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Am J Obstet Gynecol. 2013 Dec;209(6):573.e1-573.e15. doi: 10.1016/j.ajog.2013.08.005. Epub 2013 Aug 9.
Drugs of abuse affect pregnancy outcomes, however, the mechanisms in which cannabis exerts its effects are not well understood. The aim of this study was to examine the influence of short-term (1-2 hours) exposure to cannabidiol, a major phytocannabinoid, on human placental breast cancer resistance protein function.
The in vitro effect of short-term exposure to cannabidoil on breast cancer resistance protein in BeWo and Jar cells (MCF7/P-gp cells were used for comparison) was tested with mitoxantrone uptake, and nicardipine was used as positive control. The ex vivo perfused cotyledon system was used for testing the effect of cannabidoil on glyburide transport across the placenta. Glyburide (200 ng/mL) was introduced to maternal and fetal compartments through a recirculating 2 hour perfusion, and its transplacental transport was tested with (n = 8) or without (n = 8) cannabidoil.
(1) Cannabidoil inhibition of breast cancer resistance protein-dependent mitoxantrone efflux was concentration dependent and of a noncell type specific nature (P < .0001); (2) In the cotyledon perfusion assay, the administration of cannabidoil to the maternal perfusion media increased the female/male ratio of glyburide concentrations (1.3 ± 0.1 vs 0.8 ± 0.1 at 120 minutes of perfusion, P < .001).
(1) Placental breast cancer resistance protein function is inhibited following even a short-term exposure to cannabidoil; (2) the ex vivo perfusion assay emphasize this effect by increased placental penetration of glyburide to the fetal compartment; and (3) these findings suggest that marijuana consumption enhances placental barrier permeability to xenobiotics and could endanger the developing fetus. Thus, the safety of drugs that are breast cancer resistance protein substrates is questionable during cannabis consumption by pregnant women.
滥用药物会影响妊娠结局,但大麻发挥作用的机制尚不清楚。本研究旨在探讨短期(1-2 小时)暴露于大麻素 CBD 对人胎盘乳腺癌耐药蛋白功能的影响。
用米托蒽醌摄取试验检测短期暴露于 CBD 对 BeWo 和 Jar 细胞(MCF7/P-gp 细胞用于比较)中乳腺癌耐药蛋白的影响,并用尼卡地平作为阳性对照。用体外灌注胎盘系统检测 CBD 对胎盘葡萄糖醛酸转运的影响。将 200ng/ml 的格列吡嗪通过循环 2 小时灌注引入母体和胎儿室,并在(n=8)或不在(n=8)CBD 的情况下检测其跨胎盘转运。
(1)CBD 抑制乳腺癌耐药蛋白依赖性米托蒽醌外排呈浓度依赖性,且无细胞类型特异性(P<0.0001);(2)在胎盘灌注试验中,将 CBD 给予母体灌注液可增加格列吡嗪的女性/男性比值(灌注 120 分钟时为 1.3±0.1 与 0.8±0.1,P<0.001)。
(1)即使短期暴露于 CBD,胎盘乳腺癌耐药蛋白功能也会受到抑制;(2)体外灌注试验通过增加格列吡嗪向胎儿室的胎盘渗透来强调这种作用;(3)这些发现表明,大麻的使用增加了胎盘对异生素的屏障通透性,并可能危及发育中的胎儿。因此,在孕妇吸食大麻期间,作为乳腺癌耐药蛋白底物的药物的安全性值得怀疑。